Skip to main content

Table 1 Characteristics of the randomized placebo-controlled trials considered for the guideline in episodic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Study

Study phase

Treatment regimen

Duration of treatment

Participants (n)

Women (%)

Age range (years)

Monthly migraine days (range)

Preventive treatment (% using)

Exclusion by preventive failure (n. of drugs/ categories)

Eptinezumab

 Dodick, 2014 [32]

II

1000 mg quarterly ev

3 months

174

80–83

18–55

5–14

Not Allowed

Erenumab

 Sun, 2016 [44]

II

70 mg monthly sc

3 months

483

77–83

18–60

4–14

Not allowed

> 2

 STRIVE [36]

III

70 mg monthly sc

140 mg monthly sc

6 months

955

85–86

18–65

4–14

2–3

> 2

 ARISE [35]

III

70 mg monthly sc

3 months

577

85–86

18–65

4–14

6–7

> 2

Fremanezumab

 Bigal, 2015 [27]

II

225 mg (225 mg quarterly) sc

675 mg (225 mg monthly) sc

3 months

297

85–91

18–65

8–14

27–34

> 2

 HALO EM [34]

III

225 mg monthly sc

675 mg quarterly sc

3 months

875

84–86

18–70

6–14

20–21

≥2

Galcanezumab

 Dodick, 2014 [33]

II

150 mg every two weeks sc

3 months

218

82–87

18–65

4–14

Not Allowed

> 2

 Skljarevski, 2018 [42]

II

120 mg monthly sc

300 mg monthly sc

3 months

410

80–85

18–65

4–14

NR

> 2

 EVOLVE-1 [43]

III

120 mg monthly sc (240 mg ld)

240 mg monthly sc

6 months

858

83–85

18–65

4–14

Not allowed

> 2

 EVOLVE-2 [51]

III

120 mg monthly sc (240 mg ld)

240 mg monthly sc

6 months

922

85–86

18–65

4–14

Not allowed

> 2

  1. ev: endovenous; sc: subcutaneous; ld loading dose; NR: not reported.
  2. Reported treatment regimen in the Fremanezumab study is 225 mg monthly.
  3. For the Galcanezumab study, the originally published line for EVOLVE-2 was replaced with Skljarevski, 2018. A new row was introduced for EVOLVE-2, linked to reference 51